Announcement • Apr 09
Nexus AG announces Annual dividend, payable on May 27, 2025 Nexus AG announced Annual dividend of EUR 0.2300 per share payable on May 27, 2025, ex-date on May 23, 2025 and record date on May 26, 2025. Reported Earnings • Nov 07
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2024 results: EPS: €0.46 (up from €0.42 in 3Q 2023). Revenue: €66.0m (up 9.6% from 3Q 2023). Net income: €7.90m (up 7.5% from 3Q 2023). Profit margin: 12% (in line with 3Q 2023). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) exceeded analyst estimates by 28%. Revenue is forecast to grow 9.7% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. New Risk • Nov 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 4.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to €68.40, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 16x in the Healthcare Services industry in Europe. Total loss to shareholders of 12% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €90.92 per share. Reported Earnings • Aug 14
Second quarter 2024 earnings released: EPS: €0.34 (vs €0.30 in 2Q 2023) Second quarter 2024 results: EPS: €0.34 (up from €0.30 in 2Q 2023). Revenue: €67.0m (up 16% from 2Q 2023). Net income: €5.83m (up 13% from 2Q 2023). Profit margin: 8.7% (down from 9.0% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Reported Earnings • May 17
First quarter 2024 earnings released: EPS: €0.38 (vs €0.33 in 1Q 2023) First quarter 2024 results: EPS: €0.38 (up from €0.33 in 1Q 2023). Revenue: €66.4m (up 19% from 1Q 2023). Net income: €6.57m (up 16% from 1Q 2023). Profit margin: 9.9% (in line with 1Q 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Upcoming Dividend • May 09
Upcoming dividend of €0.22 per share Eligible shareholders must have bought the stock before 16 May 2024. Payment date: 21 May 2024. Payout ratio is a comfortable 16% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.7%). Declared Dividend • Apr 05
Dividend increased to €0.22 Dividend of €0.22 is 4.8% higher than last year. Ex-date: 16th May 2024 Payment date: 20th May 2024 Dividend yield will be 0.4%, which is lower than the industry average of 0.9%. Payout Ratios Payout ratio: 16%. Cash payout ratio: 18%. Reported Earnings • Mar 07
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2023 results: EPS: €1.39 (up from €1.21 in FY 2022). Revenue: €249.8m (up 18% from FY 2022). Net income: €24.0m (up 24% from FY 2022). Profit margin: 9.6% (in line with FY 2022). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates by 4.2%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 08
Third quarter 2023 earnings released: EPS: €0.42 (vs €0.28 in 3Q 2022) Third quarter 2023 results: EPS: €0.42 (up from €0.28 in 3Q 2022). Revenue: €62.4m (up 22% from 3Q 2022). Net income: €7.35m (up 66% from 3Q 2022). Profit margin: 12% (up from 8.6% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Buying Opportunity • Oct 09
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 19%. The fair value is estimated to be €59.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings is also forecast to grow by 17% per annum over the same time period. Upcoming Dividend • May 10
Upcoming dividend of €0.21 per share at 0.4% yield Eligible shareholders must have bought the stock before 17 May 2023. Payment date: 22 May 2023. Payout ratio is a comfortable 17% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.3%). Reported Earnings • Mar 09
Full year 2022 earnings released: EPS: €1.21 (vs €1.09 in FY 2021) Full year 2022 results: EPS: €1.21 (up from €1.09 in FY 2021). Revenue: €211.5m (up 11% from FY 2021). Net income: €19.3m (up 13% from FY 2021). Profit margin: 9.1% (up from 9.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 8.5% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year. Announcement • Dec 23
Nexus AG to Report First Half, 2023 Results on Aug 15, 2023 Nexus AG announced that they will report first half, 2023 results on Aug 15, 2023 Announcement • Dec 08
Nexus AG to Report Fiscal Year 2022 Results on Mar 07, 2023 Nexus AG announced that they will report fiscal year 2022 results on Mar 07, 2023 Valuation Update With 7 Day Price Move • Oct 24
Investor sentiment improved over the past week After last week's 16% share price gain to €54.00, the stock trades at a forward P/E ratio of 35x. Average forward P/E is 26x in the Healthcare Services industry in Europe. Total returns to shareholders of 70% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €50.85 per share. Price Target Changed • Sep 02
Price target decreased to €64.17 Down from €70.00, the current price target is an average from 6 analysts. New target price is 31% above last closing price of €48.95. Stock is down 28% over the past year. The company is forecast to post earnings per share of €1.37 for next year compared to €1.09 last year. Reported Earnings • Aug 21
Second quarter 2022 earnings released: EPS: €0.31 (vs €0.24 in 2Q 2021) Second quarter 2022 results: EPS: €0.31 (up from €0.24 in 2Q 2021). Revenue: €51.1m (up 7.4% from 2Q 2021). Net income: €4.94m (up 28% from 2Q 2021). Profit margin: 9.7% (up from 8.1% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 12%, compared to a 16% growth forecast for the Healthcare Services industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year whereas the company’s share price has increased by 20% per year. Reported Earnings • May 18
First quarter 2022 earnings: EPS misses analyst expectations First quarter 2022 results: EPS: €0.27 (up from €0.23 in 1Q 2021). Revenue: €51.6m (up 16% from 1Q 2021). Net income: €4.17m (up 13% from 1Q 2021). Profit margin: 8.1% (down from 8.3% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.3%. Over the next year, revenue is forecast to grow 11%, compared to a 23% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 23% per year. Price Target Changed • May 17
Price target decreased to €70.00 Down from €76.00, the current price target is an average from 6 analysts. New target price is 36% above last closing price of €51.60. Stock is down 15% over the past year. The company is forecast to post earnings per share of €1.41 for next year compared to €1.09 last year. Upcoming Dividend • Apr 27
Upcoming dividend of €0.20 per share Eligible shareholders must have bought the stock before 02 May 2022. Payment date: 04 May 2022. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.0%). Lower than average of industry peers (1.3%). Reported Earnings • Mar 10
Full year 2021 earnings: Revenues in line with analyst expectations Full year 2021 results: Net income: €17.2m (up 15% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Mar 10
Nexus AG Proposes to Pay A Dividend Nexus AG announced that at the annual general meeting on April 29, 2022, the Supervisory Board and the Executive Board will propose to pay a dividend of EUR 0.20 per share. Reported Earnings • Nov 11
Third quarter 2021 earnings released: EPS €0.22 (vs €0.17 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: €48.5m (up 26% from 3Q 2020). Net income: €3.40m (up 28% from 3Q 2020). Profit margin: 7.0% (up from 6.9% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Nov 10
Price target increased to €76.00 Up from €68.80, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €76.20. Stock is up 62% over the past year. The company is forecast to post earnings per share of €1.16 for next year compared to €0.95 last year. Price Target Changed • Aug 11
Price target increased to €68.80 Up from €63.25, the current price target is an average from 5 analysts. New target price is approximately in line with last closing price of €69.80. Stock is up 62% over the past year. Reported Earnings • Aug 09
Second quarter 2021 earnings released: EPS €0.24 (vs €0.20 in 2Q 2020) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2021 results: Revenue: €47.6m (up 21% from 2Q 2020). Net income: €3.85m (up 20% from 2Q 2020). Profit margin: 8.1% (down from 8.2% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 38% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 24
Nexus AG (XTRA:NXU) acquired Dc-Systeme Informatik Gmbh. Nexus AG (XTRA:NXU) acquired Dc-Systeme Informatik Gmbh on June 22, 2021.
Nexus AG (XTRA:NXU) completed the acquisition of Dc-Systeme Informatik Gmbh on June 22, 2021. Reported Earnings • May 14
First quarter 2021 earnings released: EPS €0.23 (vs €0.19 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €45.6m (up 15% from 1Q 2020). Net income: €3.68m (up 26% from 1Q 2020). Profit margin: 8.1% (up from 7.4% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has increased by 29% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Apr 21
Upcoming dividend of €0.19 per share Eligible shareholders must have bought the stock before 28 April 2021. Payment date: 30 April 2021. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (1.0%). Analyst Estimate Surprise Post Earnings • Mar 12
Revenue and earnings beat expectations Revenue exceeded analyst estimates by 0.6%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Over the next year, revenue is forecast to grow 9.5%, compared to a 490% growth forecast for the Healthcare Services industry in Germany. Reported Earnings • Mar 11
Full year 2020 earnings released: EPS €0.95 (vs €0.69 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: €166.0m (up 9.5% from FY 2019). Net income: €14.9m (up 38% from FY 2019). Profit margin: 9.0% (up from 7.2% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Is New 90 Day High Low • Jan 08
New 90-day high: €55.00 The company is up 18% from its price of €46.80 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €57.58 per share. Analyst Estimate Surprise Post Earnings • Nov 14
Earnings beat expectations, revenue disappoints Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) exceeded analyst estimates by 4.5%. Over the next year, revenue is forecast to grow 9.9%, compared to a 235% growth forecast for the Healthcare Services industry in Germany. Reported Earnings • Nov 14
Third quarter 2020 earnings released: EPS €0.17 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: €38.6m (up 3.0% from 3Q 2019). Net income: €2.65m (up 11% from 3Q 2019). Profit margin: 6.9% (up from 6.3% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has increased by 26% per year, which means it is tracking significantly ahead of earnings growth. Price Target Changed • Nov 13
Price target raised to €49.83 Up from €45.17, the current price target is an average from 3 analysts. The new target price is close to the current share price of €48.10. As of last close, the stock is up 34% over the past year. Is New 90 Day High Low • Nov 03
New 90-day high: €51.60 The company is up 19% from its price of €43.20 on 05 August 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare Services industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €36.69 per share. Announcement • Oct 02
Nexus AG (XTRA:NXU) acquired approximately 93% stake in RVC Medical IT from Main Capital Partners B.V. Nexus AG (XTRA:NXU) acquired approximately 93% stake in RVC Medical IT from Main Capital Partners B.V. on September 30, 2020. RVC will remain an independent company with its sites and will actively exploit synergies of the Nexus Group within the context of an integration project.
Nexus AG (XTRA:NXU) completed the acquisition of approximately 93% stake in RVC Medical IT from Main Capital Partners B.V. on September 30, 2020.